ProQR Therapeutics NV PRQR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.88
- Day Range
- $1.79–1.90
- 52-Week Range
- $1.33–3.10
- Bid/Ask
- $1.81 / $1.82
- Shares Outstanding
- 141.12M
- Market Cap
- $255.43M
- Volume/Avg
- 824,682 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 187
- Website
- https://www.proqr.com
Valuation
|
Metric
|
PRQR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 17.75 |
Price/Sales | 12.73 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PRQR
|
|---|---|
Quick Ratio | 2.48 |
Current Ratio | 2.48 |
Interest Coverage | — |
Quick Ratio
PRQR
Profitability
|
Metric
|
PRQR
|
|---|---|
Return on Assets (Normalized) | −33.59% |
Return on Equity (Normalized) | −115.11% |
Return on Invested Capital (Normalized) | −57.65% |
Return on Assets
PRQR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@hpzbX^ | LOCK|%x%F$ | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$%y?D? | LOCK|N<#< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|x&R?%T | LOCK|Dm< | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Tq>wBK | LOCK|l<q | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%%X?sw | LOCK|JSJ% | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hzVcgC<W | LOCK|&^gZv | $26B | |||
| Moderna Inc
MRNA
| LOCK|$!<>St | LOCK|m%l | $24B | |||
| Incyte Corp
INCY
| LOCK|mynP^#^ | LOCK|$S | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>!dd&M | LOCK|d!& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|JsHWG& | LOCK|tk | $16B |
United States